RTTR - リタ―・ファ―マシュ―ティカルズ (Ritter Pharmaceuticals Inc.) リタ―・ファ―マシュ―ティカルズ

 RTTRのチャート


 RTTRの企業情報

symbol RTTR
会社名 Ritter Pharmaceuticals Inc (リタ―・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Ritter Pharmaceuticals Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company''s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient''s health. The Company''s compound RP-G28 is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate RP-G28 an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.   リタ―・ファ―マシュ―ティカルズは、米国の臨床段階の製薬会社。消化器系統で乳糖(ラクト―ス)の消化酵素(ラクタ―ゼ)が減少して生じる諸症状の治療薬を開発する。また、胃腸の健康状態を全般的に改善するための方法および組成物を提供する。本社はカリフォルニア州ロサンゼルス。   Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.
本社所在地 1880 Century Park East Suite 1000 Los Angeles CA 90067 USA
代表者氏名 Ira E. Ritter アイラE.リッター
代表者役職名 Executive Chairman of the Board Chief Strategic Officer
電話番号 +1 310-203-1000
設立年月日 38047
市場名 NASDAQ Small Cap
ipoyear 2015年
従業員数
url www.ritterpharmaceuticals.com
nasdaq_url https://www.nasdaq.com/symbol/rttr
adr_tso
EBITDA EBITDA(百万ドル) -9.89111
終値(lastsale) 1.94
時価総額(marketcap) 10737199.66
時価総額 時価総額(百万ドル) 9.29819
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -2.71429
当期純利益 当期純利益(百万ドル) -12.93596
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Ritter Pharmaceuticals Inc revenues was not reported. Net loss increased 54% to $5.6M. Higher net loss reflects Research and Development increase from $1.2M to $2.7M (expense) General and administrative increase of 21% to $2.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.85 to -$1.11.

 RTTRのテクニカル分析


 RTTRのニュース

   Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement  2020/01/21 14:15:00 GlobeNewswire
Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs …
   Ritter Pharmaceuticals Inc (NASDAQ:RTTR) Short Interest Down 44.4% in October  2019/11/16 04:40:46 Modern Readers
Ritter Pharmaceuticals Inc (NASDAQ:RTTR) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 318,500 shares, a decrease of 44.4% from the September 30th total of 572,800 shares. Based on an average trading volume of 978,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 3.5% of […]
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   Ritter Pharma to explore strategic alternatives; shares ahead 20%  2019/10/07 15:44:36 Seeking Alpha
Nano cap Ritter Pharmaceuticals ([[RTTR]] +20.3%) is up on almost a 4x surge in volume on the heels of its announcement it has engaged A.G.P./Alliance Glob
   Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives  2019/10/07 13:00:00 ACI Information Group
LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, announced that it has engaged A.G.P./Alliance Global Partners
   Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement  2020/01/21 14:15:00 GlobeNewswire
Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs …
   Ritter Pharmaceuticals Inc (NASDAQ:RTTR) Short Interest Down 44.4% in October  2019/11/16 04:40:46 Modern Readers
Ritter Pharmaceuticals Inc (NASDAQ:RTTR) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 318,500 shares, a decrease of 44.4% from the September 30th total of 572,800 shares. Based on an average trading volume of 978,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 3.5% of […]
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   Ritter Pharma to explore strategic alternatives; shares ahead 20%  2019/10/07 15:44:36 Seeking Alpha
Nano cap Ritter Pharmaceuticals ([[RTTR]] +20.3%) is up on almost a 4x surge in volume on the heels of its announcement it has engaged A.G.P./Alliance Glob
   Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives  2019/10/07 13:00:00 ACI Information Group
LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, announced that it has engaged A.G.P./Alliance Global Partners
   Ritter Pharmaceuticals Inc (NASDAQ:RTTR) Short Interest Down 44.4% in October  2019/11/16 04:40:46 Modern Readers
Ritter Pharmaceuticals Inc (NASDAQ:RTTR) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 318,500 shares, a decrease of 44.4% from the September 30th total of 572,800 shares. Based on an average trading volume of 978,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 3.5% of […]
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   Ritter Pharma to explore strategic alternatives; shares ahead 20%  2019/10/07 15:44:36 Seeking Alpha
Nano cap Ritter Pharmaceuticals ([[RTTR]] +20.3%) is up on almost a 4x surge in volume on the heels of its announcement it has engaged A.G.P./Alliance Glob
   Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives  2019/10/07 13:00:00 ACI Information Group
LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, announced that it has engaged A.G.P./Alliance Global Partners
   The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck  2019/09/15 15:18:11 Benzinga
Biotech stocks rebounded in last week after declining modestly in the previous week. Some of the drugs that cleared the FDA hurdle this week include Ardelyx Inc (NASDAQ: ARDX )'s constipation drug Ibsrela; South African drugmaker Apsen Pharmacare's hydroxyprogesterone caproate, indicated to prevent preterm birth in pregnant women; and GlaxoSmithKline plc (NYSE: GSK )'s Nucala for treating severe eosinophilic asthma in children, ages 8-11 years. The week turned out to be a disappointing one for a few nano- and micro-cap stocks, which reported negative clinical trial readouts. Tocagen Inc (NASDAQ: TOCA ) tumbled about 78% after its brain cancer drug failed to ace a late-stage study and Ritter Pharmaceuticals Inc (NASDAQ: RTTR )'s pipeline asset to treat lactose intolerance also stumbled in a late-stage study, sending its shares to a record low. Here are the key catalysts a biotech investor needs to focus on for the upcoming week. Conferences Retina Society Annual Meeting 2019 Annual Meeting – Sept. 11-15, in London Global Summit On Cardiology & Heart Diseases – Sept. 16-17, in Dubai European Association for the Study of Diabetes, or EASD, 55th annual meeting – Sept. 16-20, in Barcelona, Spain 13th European Pediatric Neurology Society, or EPNS, Congress – Sept. 17 – 21, in Athens, Greece 4th Antibodies, Antibiotics and Bio …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 リタ―・ファ―マシュ―ティカルズ RTTR Ritter Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)